Market Exclusive

Fennec Pharmaceuticals Inc (NASDAQ:FENC) had its Outperform rating reiterated by Wedbush with a $16.00 price target

Analyst Ratings For Fennec Pharmaceuticals Inc (NASDAQ:FENC)

Today, Wedbush reiterated its Outperform rating on Fennec Pharmaceuticals Inc (NASDAQ:FENC) with a price target of $16.00.

There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Fennec Pharmaceuticals Inc (NASDAQ:FENC) is Buy with a consensus target price of $17.00 per share, a potential 182.86% upside.

Some recent analyst ratings include

About Fennec Pharmaceuticals Inc (NASDAQ:FENC)
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Recent Trading Activity for Fennec Pharmaceuticals Inc (NASDAQ:FENC)
Shares of Fennec Pharmaceuticals Inc closed the previous trading session at 6,01 −0,84 12,26 % with shares trading hands.

Exit mobile version